Reviewing Merrimack Pharmaceuticals Inc. (MACK)’s and Pacific Biosciences of California Inc. (NASDAQ:PACB)’s results

Both Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) and Pacific Biosciences of California Inc. (NASDAQ:PACB) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Merrimack Pharmaceuticals Inc. N/A 0.00 53.44M -4.55 0.00
Pacific Biosciences of California Inc. 75.69M 13.41 108.71M -0.76 0.00

Table 1 demonstrates Merrimack Pharmaceuticals Inc. and Pacific Biosciences of California Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us Merrimack Pharmaceuticals Inc. and Pacific Biosciences of California Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Merrimack Pharmaceuticals Inc. 0.00% -66.6% -48.1%
Pacific Biosciences of California Inc. -143.63% -102% -64.3%

Risk and Volatility

Merrimack Pharmaceuticals Inc. has a 2.37 beta, while its volatility is 137.00%, thus making it more volatile than S&P 500. Pacific Biosciences of California Inc.’s 2.32 beta is the reason why it is 132.00% more volatile than S&P 500.

Liquidity

The current Quick Ratio of Merrimack Pharmaceuticals Inc. is 5.1 while its Current Ratio is 5.1. Meanwhile, Pacific Biosciences of California Inc. has a Current Ratio of 2.5 while its Quick Ratio is 2.1. Merrimack Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Pacific Biosciences of California Inc.

Dividends

Merrimack Pharmaceuticals Inc. pays out $10.55 per share annually while its annual dividend yield is 185.09%. Pacific Biosciences of California Inc. does not pay a dividend.

Analyst Recommendations

In next table is delivered Merrimack Pharmaceuticals Inc. and Pacific Biosciences of California Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Merrimack Pharmaceuticals Inc. 0 0 0 0.00
Pacific Biosciences of California Inc. 0 2 0 2.00

Meanwhile, Pacific Biosciences of California Inc.’s consensus price target is $8, while its potential upside is 20.30%.

Insider and Institutional Ownership

Institutional investors owned 57.2% of Merrimack Pharmaceuticals Inc. shares and 76.4% of Pacific Biosciences of California Inc. shares. Insiders owned roughly 4.09% of Merrimack Pharmaceuticals Inc.’s shares. Comparatively, Pacific Biosciences of California Inc. has 2.3% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Merrimack Pharmaceuticals Inc. 1.53% 1.71% -0.67% 37.01% -32.27% 54.4%
Pacific Biosciences of California Inc. 1.09% 0.82% 4.53% -4.52% 205.37% -0.14%

For the past year Merrimack Pharmaceuticals Inc. had bullish trend while Pacific Biosciences of California Inc. had bearish trend.

Summary

Merrimack Pharmaceuticals Inc. beats on 7 of the 11 factors Pacific Biosciences of California Inc.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. Its therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.